BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $290.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $290.00M, a 88.57% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $2.54B.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $290.00M 10-K · filed 2026-02-11 | |
| 2024-12-31 | $2.54B 10-K · filed 2026-02-11 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-11 | $325.00M 10-K · filed 2024-02-13 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-12 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-14 | |
| 2020-12-31 | $2.46B 10-K · filed 2023-02-14 | |
| 2019-12-31 | $5.00M 10-K · filed 2022-02-09 | |
| 2018-12-31 | $17.00M 10-K · filed 2021-02-10 | |
| 2017-12-31 | $266.00M 10-K · filed 2020-02-24 | |
| 2016-12-31 | $100.00M 10-K · filed 2019-02-25 | |
| 2015-12-31 | $369.00M 10-K · filed 2018-02-13 | |
| 2014-12-31 | $52.00M 10-K · filed 2017-02-21 | |
| 2008-12-31 | $11.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |